BIOMARIN PHARMACEUTICAL INC

03/06/2008(1)

03/06/2008

S

1,200

D

101,264

D

Form 4

March 10, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to **SECURITIES** Section 16. Form 4 or

> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

Form 5

obligations

may continue.

See Instruction

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading KAKKIS EMIL D Issuer Symbol **BIOMARIN PHARMACEUTICAL** (Check all applicable) INC [BMRN] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X_ Officer (give title Other (specify (Month/Day/Year) below) C/O BIOMARIN 03/06/2008 Chief Medical Officer PHARMACEUTICAL INC., 105 DIGITAL DRIVE (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting NOVATO, CA 94949 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of Transaction(A) or Disposed of (D) Indirect Security (Month/Day/Year) Execution Date, if Securities Ownership (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Direct Beneficial (D) or (Month/Day/Year) (Instr. 8) Owned Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4) (A) Transaction(s) or (Instr. 3 and 4) Code V (D) Price Amount Common 03/06/2008(1) 03/06/2008 \$4 D M 18,000 Α 104,164 Stock Common 03/06/2008(1) 03/06/2008 S 100 D 104,064 D 37.99 Stock Common 03/06/2008(1) S 300 \$38 03/06/2008 D 103,764 D Stock Common S 1,300 D 03/06/2008(1) 03/06/2008 102,464 D 38.01 Stock

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

ommon ock						\$ 38.02		
ommon ock	03/06/2008(1)	03/06/2008	S	500	D	\$ 38.03	100,764	D
ommon ock	03/06/2008(1)	03/06/2008	S	1,200	D	\$ 38.04	99,564	D
ommon ock	03/06/2008(1)	03/06/2008	S	500	D	\$ 38.05	99,064	D
ommon ock	03/06/2008(1)	03/06/2008	S	500	D	\$ 38.06	98,564	D
ommon ock	03/06/2008(1)	03/06/2008	S	400	D	\$ 38.07	98,164	D
ommon ock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.08	97,964	D
ommon ock	03/06/2008(1)	03/06/2008	S	300	D	\$ 38.1	97,664	D
ommon ock	03/06/2008(1)	03/06/2008	S	400	D	\$ 38.11	97,264	D
ommon ock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.12	97,064	D
ommon ock	03/06/2008(1)	03/06/2008	S	800	D	\$ 38.13	96,264	D
ommon ock	03/06/2008(1)	03/06/2008	S	400	D	\$ 38.14	95,864	D
ommon ock	03/06/2008(1)	03/06/2008	S	300	D	\$ 38.15	95,564	D
ommon ock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.16	95,364	D
ommon ock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.2	95,164	D
ommon ock	03/06/2008(1)	03/06/2008	S	300	D	\$ 38.21	94,864	D
ommon ock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.22	94,664	D
ommon ock	03/06/2008(1)	03/06/2008	S	500	D	\$ 38.23	94,164	D
ommon ock	03/06/2008(1)	03/06/2008	S	700	D	\$ 38.24	93,464	D
ommon ock	03/06/2008(1)	03/06/2008	S	3,000	D	\$ 38.25	90,464	D
	03/06/2008(1)	03/06/2008	S	2,300	D		88,164	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock						\$ 38.26			
Common Stock	03/06/2008(1)	03/06/2008	S	1,500	D	\$ 38.27	86,664	D	
Common Stock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.29	86,464	D	
Common Stock	03/06/2008(1)	03/06/2008	S	200	D	\$ 38.31	86,264	D	
Common Stock	03/06/2008(1)	03/06/2008	S	100	D	\$ 38.34	86,164	D	
Common Stock							4,654	I	Shares held by spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of		TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of		TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of		6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
	Security				(D) (Instr. 3, 4, and 5)								
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share				
Stock Option (right to buy)	\$ 4	03/06/2008(1)	03/06/2008	M	18,000	12/24/1998(2)	06/21/2008	Common Stock	18,000				

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

KAKKIS EMIL D Chief Medical Officer

C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE

Reporting Owners 3

NOVATO, CA 94949

Signatures

/s/ G. Eric Davis, Attorney-in-Fact 03/10/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (2) Original option grant vested 6/48ths on 12/24/1998 and 1/48th on the 24th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4